PRESENTATION · Mar 2026 · PDF
Presentations & Publications
LGMD2I/R9
PRESENTATION · Mar 2026 · PDF
BBIO-BBP-418 – MDA 2026 – Additional Data from Phase 3 FORTIFY Interim Analysis
PRESENTATION · Mar 2026 · PDF
BBIO-BBP-418 – MDA 2026 – LGMD2IR9 Health Outcomes Mode
PRESENTATION · Mar 2026 · PDF
BBIO-BBP-418 – MDA 2026 – Journey of BBP-418
PRESENTATION · Mar 2026 · PDF
BBIO-BBP-418 – MDA 2026 – Systematic Literature Review in LGMD2IR9
PRESENTATION · Mar 2025 · PDF
BBP-418 - MDA 2025 - Understanding the Burden of LGMD2I/R9
PRESENTATION · Mar 2025 · PDF
BBP-418 - MDA 2025 - Baseline Characteristics FORTIFY
PRESENTATION · Dec 2024 · PDF
BBP-418 - WMS 2024 - FORTIFY Design
PRESENTATION · Dec 2024 · PDF
BBP-418 - MENA 2024 - Oral Presentation
PRESENTATION · Dec 2024 · PDF
BBP-418 - MDA 2024 - FORTIFY Phase 3 Trial Design
PRESENTATION · Dec 2024 · PDF
BBP-418 - MDA 2024 - FORTIFY Phase 3 Trial Design
PRESENTATION · Dec 2023 · PDF
BBP-418 - WMS 2023 - Phase 2 Data at 21 Months; Ambulatory Improvements at 9 Months
PRESENTATION · Dec 2023 · PDF
BBP-418 for LGMD2I/R9 - MDA 2023 - Oral Presentation - Phase 2 Data at 15 Months
PRESENTATION · Dec 2023 · PDF
BBP-418 for LGMD2I/R9 - MDA 2023 - Poster - Phase 2 Data at 15 Months
PRESENTATION · Dec 2023 · PDF
BBP-418 for LGMD2I/R9 - MDA 2023 - Preliminary Data on Bioassay Measuring αDG
PRESENTATION · Dec 2023 · PDF